Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Preferred Stock Liabilities (2024)

Traws Pharma (TRAW) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $111.6 million as the latest value for Q2 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $111.6 million in Q2 2024 year-over-year; TTM through Jun 2024 was $111.6 million, a N/A change, with the full-year FY2012 number at $201.3 million, up 67.77% from a year prior.
  • Preferred Stock Liabilities was $111.6 million for Q2 2024 at Traws Pharma, down from $203.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $111.6 million in Q2 2024 to a low of $111.6 million in Q2 2024.